US equities
|
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Oncolytics Biotech Inc. - Common Stock
(NQ:
ONCY
)
0.4254
-0.0023 (-0.54%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Oncolytics Biotech Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
March 05, 2024
US$5M grant supports study of pelareorep in combination with modified FOLFIRINOX +/- atezolizumab Testing with the most common therapies could facilitate broad use of pelareorep in pancreatic cancer...
Via
FinancialNewsMedia
Cancer Immunotherapy Stocks – Tapping into Immune Systems for Next Generation Treatments
February 15, 2024
Vancouver, Kelowna and Delta, British Columbia – February 15, 2024) – Investorideas.com, a global investor news source covering biotech and pharma stocks issues a sector snapshot on cancer...
Via
FinancialNewsMedia
Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments
February 15, 2024
Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - February 15, 2024) - Investorideas.com, a global investor news source covering biotech...
Via
Newsfile
Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
February 14, 2024
Successful Stage 1 data showed a near tripling of Objective Response Rate compared to checkpoint inhibitor monotherapy, including a Complete Response, and supports expansion San Diego, CA and Calgary,...
Via
FinancialNewsMedia
Oncolytics Biotech's Earnings Outlook
↗
November 02, 2023
Via
Benzinga
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
February 14, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Pancreatic Cancer Treatments Poised for Major Advances in 2024
February 07, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
February 14, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
January 09, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END
Via
FinancialNewsMedia
Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors
January 09, 2024
SAN DIEGO, CA and CALGARY, AB – January 9, 2024 – Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the appointment of...
Via
FinancialNewsMedia
Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024
January 04, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC) EQNX::TICKER_END
Via
FinancialNewsMedia
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
January 09, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
November 29, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance
November 09, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:BMY),(NASDAQ:GILD),(NYSE:MRK),(NYSE:PFE) EQNX::TICKER_END
Via
FinancialNewsMedia
Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy
November 09, 2023
Pelareorep-atezolizumab combination data exceeds historical control trials with a 37.5% objective response rate, including a complete response San Diego, CA, and Calgary, AB – November 9, 2023 –...
Via
FinancialNewsMedia
Earnings Scheduled For November 3, 2023
↗
November 03, 2023
Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million.
Via
Benzinga
Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise
October 23, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(OTCQX:RHHBY),(NASDAQ:BNTX),(NASDAQ:ME) EQNX::TICKER_END
Via
FinancialNewsMedia
Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing
October 23, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:LIPO) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study
October 23, 2023
Results met efficacy criteria for enrollment expansion and provide support for pelareorep’s mechanism of action San Diego, CA and Calgary, AB – October 23, 2023 – Oncolytics Biotech® Inc. (NASDAQ:...
Via
FinancialNewsMedia
Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO
October 23, 2023
7.2 months mPFS and 10.6 months interim median OS surpass historical outcomes by ≥ 25% T-cell expansion data correlate with tumor response, providing important proof-of-concept San Diego, CA and...
Via
FinancialNewsMedia
Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research
October 20, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:BNTX),(NASDAQ:SGEN),(NASDAQ:MYGN),(NASDAQ:ILMN) EQNX::TICKER_END
Via
FinancialNewsMedia
Oncolytics Biotech® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023
October 16, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC) EQNX::TICKER_END
Via
FinancialNewsMedia
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
October 13, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END
Via
FinancialNewsMedia
Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment
October 11, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GNLX),(NASDAQ:CRNX),(NYSE:PFE),(NASDAQ:SGEN) EQNX::TICKER_END
Via
FinancialNewsMedia
Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases
September 26, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 26, 2023 – USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since The...
Via
FinancialNewsMedia
THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS
September 26, 2023
Innovative Multimillion-Dollar Grant Was Created in 2022 to Drive Biopharma Industry to Speed Development of Pancreatic Cancer Therapies BOSTON, MA., San Diego, CA., and Calgary, AB. – September 26,...
Via
FinancialNewsMedia
Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise
September 26, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:VACC),(NASDAQ:BPTS),(NASDAQ:RNAZ),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
September 22, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal,...
Via
FinancialNewsMedia
On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope
September 20, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 20, 2023 – USA News Group – Earlier this year, the US White House requested over $2.8 billion in funding from Congress...
Via
FinancialNewsMedia
Pancreatic Cancer Battle Boosted by $200M VC Firm
September 19, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:MACK),(NASDAQ:INCY),(NASDAQ:MRTX),(NASDAQ:BNTX) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
< Previous
1
2
3
4
5
6
7
8
Next >
